These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 36281767)

  • 61. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
    Femminella GD; Frangou E; Love SB; Busza G; Holmes C; Ritchie C; Lawrence R; McFarlane B; Tadros G; Ridha BH; Bannister C; Walker Z; Archer H; Coulthard E; Underwood BR; Prasanna A; Koranteng P; Karim S; Junaid K; McGuinness B; Nilforooshan R; Macharouthu A; Donaldson A; Thacker S; Russell G; Malik N; Mate V; Knight L; Kshemendran S; Harrison J; Hölscher C; Brooks DJ; Passmore AP; Ballard C; Edison P
    Trials; 2019 Apr; 20(1):191. PubMed ID: 30944040
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Application of Repetitive Transcranial Magnetic Stimulation over the Dorsolateral Prefrontal Cortex in Alzheimer's Disease: A Pilot Study.
    Mano T
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160250
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment of Executive Function Deficits in autism spectrum disorder with repetitive transcranial magnetic stimulation: A double-blind, sham-controlled, pilot trial.
    Ameis SH; Blumberger DM; Croarkin PE; Mabbott DJ; Lai MC; Desarkar P; Szatmari P; Daskalakis ZJ
    Brain Stimul; 2020; 13(3):539-547. PubMed ID: 32289673
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exercise priming with transcranial direct current stimulation: a study protocol for a randomized, parallel-design, sham-controlled trial in mild cognitive impairment and Alzheimer's disease.
    Liu CS; Herrmann N; Song BX; Ba J; Gallagher D; Oh PI; Marzolini S; Rajji TK; Charles J; Papneja P; Rapoport MJ; Andreazza AC; Vieira D; Kiss A; Lanctôt KL
    BMC Geriatr; 2021 Dec; 21(1):677. PubMed ID: 34863115
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Distinct reserve capacity impacts on default-mode network in response to left angular gyrus-navigated repetitive transcranial magnetic stimulation in the prodromal Alzheimer disease.
    Lv T; You S; Qin R; Hu Z; Ke Z; Yao W; Zhao H; Xu Y; Bai F
    Behav Brain Res; 2023 Feb; 439():114226. PubMed ID: 36436729
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increased migraine-free intervals with multifocal repetitive transcranial magnetic stimulation.
    Leahu P; Bange M; Ciolac D; Scheiter S; Matei A; Gonzalez-Escamilla G; Chirumamilla VC; Groppa SA; Muthuraman M; Groppa S
    Brain Stimul; 2021; 14(6):1544-1552. PubMed ID: 34673259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study.
    Rumi DO; Gattaz WF; Rigonatti SP; Rosa MA; Fregni F; Rosa MO; Mansur C; Myczkowski ML; Moreno RA; Marcolin MA
    Biol Psychiatry; 2005 Jan; 57(2):162-6. PubMed ID: 15652875
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial.
    Attal N; Poindessous-Jazat F; De Chauvigny E; Quesada C; Mhalla A; Ayache SS; Fermanian C; Nizard J; Peyron R; Lefaucheur JP; Bouhassira D
    Brain; 2021 Dec; 144(11):3328-3339. PubMed ID: 34196698
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of multisite anodal transcranial direct current stimulation combined with cognitive stimulation in patients with Alzheimer's disease and its neurophysiological correlates: A double-blind randomized clinical trial.
    Andrade SM; Machado DGDS; Silva-Sauerc LD; Regis CT; Mendes CKTT; de Araújo JSS; de Araújo KDT; Costa LP; Queiroz MEBS; Leitão MM; Fernández-Calvo B
    Neurophysiol Clin; 2022 Apr; 52(2):117-127. PubMed ID: 35339351
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: A randomized, double-blind, sham-controlled trial.
    Martinotti G; Pettorruso M; Montemitro C; Spagnolo PA; Acuti Martellucci C; Di Carlo F; Fanella F; di Giannantonio M;
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jun; 116():110513. PubMed ID: 35074451
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Low-frequency rTMS in patients with subacute ischemic stroke: clinical evaluation of short and long-term outcomes and neurophysiological assessment of cortical excitability.
    Blesneag AV; Slăvoacă DF; Popa L; Stan AD; Jemna N; Isai Moldovan F; Mureșanu DF
    J Med Life; 2015; 8(3):378-87. PubMed ID: 26351545
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
    Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
    J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of masupirdine (SUVN-502) on cognition in patients with moderate Alzheimer's disease: A randomized, double-blind, phase 2, proof-of-concept study.
    Nirogi R; Ieni J; Goyal VK; Ravula J; Jetta S; Shinde A; Jayarajan P; Benade V; Palacharla VRC; Dogiparti DK; Jasti V; Atri A; Cummings J
    Alzheimers Dement (N Y); 2022; 8(1):e12307. PubMed ID: 35662833
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A randomized controlled trial of 5 daily sessions and continuous trial of 4 weekly sessions of repetitive transcranial magnetic stimulation for neuropathic pain.
    Hosomi K; Sugiyama K; Nakamura Y; Shimokawa T; Oshino S; Goto Y; Mano T; Shimizu T; Yanagisawa T; Saitoh Y;
    Pain; 2020 Feb; 161(2):351-360. PubMed ID: 31593002
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Study on the Effect of Executive Control Network Functional Connection on the Therapeutic Efficacy of Repetitive Transcranial Magnetic Stimulation in Alzheimer's Disease.
    Geng Z; Wu Y; Liu J; Zhan Y; Yan Y; Yang C; Pang X; Ji Y; Gao M; Zhou S; Wei L; Hu P; Wu X; Tian Y; Wang K
    J Alzheimers Dis; 2024; 99(4):1349-1359. PubMed ID: 38820018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.